NCT05577923尚未招募2 期
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 126
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study is a prospective, single-arm, phase II clinical study for patients with ER+/HER2+ advanced breast cancer.
详细描述
Patients with ER+/HER2+ advanced breast cancer are planned to be enrolled. Patients will receive first-line endocrine therapy combined with anti-HER2 therapy. The main purpose is to evaluate whether disease-free intervals can guide first-line endocrine combined targeted therapy for ER+/HER2+ advanced breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females ≥18 years and ≤ 75 years old;
- •Histologically confirmed ER + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER> 10% tumor cell positive is defined as ER positive, HER2 3+ or HER2 amplification followed by FISH detection);
- •Stage IV breast cancer or recurrent metastatic breast cancer;
- •Patients had received no previous chemotherapy or targeted therapy for metastatic disease
- •At least one lesion (measurable and/or non-measurable) that has not previously received radiation therapy
- •Normal heart function, normal ECG and LVEF ≥ 55%;
- •Has adequate bone marrow function: absolute neutrophil count > 1.5x10ˆ9 /L; platelet count > 75x10ˆ9 /L, hemoglobin > 9g/dL;
- •Has adequate liver function and kidney function: TBIL ≤1.5 times of the normal upper limit；ALT and AST ≤3 times of the normal upper limit；if liver metastases，then ALT and AST≤ 5 times of the normal upper limit；serum creatinine ≤1.5 times of the normal upper limit; Child-Pugh A/B（≤9 score）
- •Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.
排除标准
- •Treatment with chemotherapy, radiotherapy, immunotherapy or surgery (outpatient clinic surgery excluded) for metastatic disease
- •CNS metastases
- •Significant cardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or ventricular arrhythmia in the last 6 months);
- •is pregnant or breast feeding;
- •Malignant tumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in situ).
- •Positive test for human immunodeficiency virus
- •Active hepatitis B or hepatitis C
- •Rapid progression of the disease, researchers judge that endocrine combination targeted therapy is not suitable, including the number of liver metastases exceeding 10 or the maximum diameter of a single liver metastases ≥ 10 cm, symptomatic thoraco-ascites, etc.;
- •Subjects with uncontrolled lung disease, severe infection, active gastrointestinal ulcer, coagulopathy, severe uncontrolled diabetes, connective tissue disease or inhibition of bone marrow function who cannot tolerate therapy;
- •Current use or anticipated need for food or drugs that are known strong CYP3A4 (cytochrome P450 3A4) inhibitors or inducers.
- •Strong CYP3A inhibitors, including, boceprevir, clarithromycin, conivaptan, delavirdine, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, suboxone, telaprevir, telithromycin, voriconazole, and grapefruit, grapefruit juice or any product containing grapefruit.
- •Strong CYP3A inducers, including carbamazepine, phenytoin, primidone, rifampin, rifapentin, and St. John's wort.
- •Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever of unknown origin occurs during the screening period/before the first administration.
研究组 & 干预措施
T-sunflower group
Experimental
Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
干预措施: Trastuzumab (Drug)
T-sunflower group
Experimental
Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
干预措施: pyrotinib (Drug)
T-sunflower group
Experimental
Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
干预措施: Dalpiciclib (Drug)
T-sunflower group
Experimental
Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
干预措施: fulvestrant (Drug)
结局指标
主要结局
PFS
时间窗: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 5 years)
time to progressive disease (according to RECIST1.1)
次要结局
- ORR(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 5 years))
- CBR(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 5 years))
- DOR(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 5 years))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin TherapyBreast CancerNCT01777958Hoffmann-La Roche135
已完成
2 期
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic CancerPancreatic CancerNCT00674973Hoffmann-La Roche207
招募中
不适用
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast CancerHER2-positive Metastatic Breast CancerStage IV Breast CancerNCT05959291University of Miami20
Unknown
不适用
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRRecurrent or Metastatic Breast CancerNCT03947736Chinese Academy of Medical Sciences200
撤回
2 期
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerTriple Negative Breast CancerBreast CancerNCT03872505Cedars-Sinai Medical Center